Active Ingredient: Mogamulizumab
Mogamulizumab is indicated for the treatment of adult patients with mycosis fungoides (MF) who have received at least one prior systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
1 - 1 mg per kg of body weight
From 1 To 1 mg per kg of body weight once every 7 day(s)
The recommended dose is 1 mg/kg mogamulizumab administered as an intravenous infusion over at least 60 minutes. Administration is weekly on days 1, 8, 15 and 22 of the first 28-day cycle, followed by infusions every two weeks on Days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity.
Mogamulizumab should be administered within 2 days of the scheduled day. If a dose is missed by more than 2 days, the next dose should be administered as soon as possible, after which the dosing schedule should be resumed with doses given based on the new scheduled days.
Pre-medication with anti-pyretic and anti-histamine is recommended for the first mogamulizumab infusion. If an infusion reaction occurs, administer pre-medication for subsequent mogamulizumab infusions.
Patients receiving mogamulizumab have experienced drug rash (drug eruption), some of which were severe and/or serious.
In the event of a rash (drug related) with severity of Grade 2 or 3 (moderate or severe), treatment with mogamulizumab must be interrupted and the rash should be treated appropriately until rash improves to Grade 1 or less (mild severity), at which time mogamulizumab treatment may be resumed.
Mogamulizumab should be permanently discontinued for a life-threatening (Grade 4) rash.
The infusion of mogamulizumab should be temporarily interrupted for mild to severe (Grades 1-3) infusion-related reactions and symptoms treated. The infusion rate should be reduced by at least 50% when re-starting the infusion after symptoms resolve. If reaction recurs, discontinuing the infusion should be considered.
Mogamulizumab should be permanently discontinued for a life-threatening (Grade 4) infusion-related reaction.
It should be administered by intravenous infusion only, over at least 60 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
